New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
08:06 EDTAMRNAmarin announces notification of additional U.S. patent allowance
Amarin Corporation announced that the United States Patent and Trademark Office, or USPTO, has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/272,520 titled "Compositions and Methods for Lowering Triglycerides." This application includes claims intended to protect the proposed Vascepa indication based on Amarin's Phase 3 ANCHOR clinical trial results. Amarin is on track to file a Supplemental New Drug Application for the Vascepa ANCHOR indication with the FDA by the end of February, and expects an FDA action date on the application before the end of 2013. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, after issuance of the patent and approval of Vascepa in the ANCHOR indication. The claims in this allowed application cover a method of use relating to Vascepa's ANCHOR indication. Specifically, the allowed independent claims covers use of about 4 grams per day of highly pure icosapent ethyl, or EPA, including Vascepa, to lower triglycerides and LDL-C.
News For AMRN From The Last 14 Days
Check below for free stories on AMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
16:50 EDTAMRNAmarin files $300M mixed securities shelf
16:12 EDTAMRNAmarin reports Q2 adjusted EPS (14c), consensus (15c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use